FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026005704> ?p ?o ?g. }

• W3026005704 endingPage "104899" @default.
• W3026005704 startingPage "104899" @default.
• W3026005704 abstract "SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection. This prospective (compassionate), open-label study of remdesivir, which was conducted at Luigi Sacco Hospital, Milan, Italy, between February 23 and March 20, 2020, involved patients with SARS-CoV-2 pneumonia aged ≥18 years undergoing mechanical ventilation or with an oxygen saturation level of ≤94 % in air or a National Early Warning Score 2 of ≥4. The primary outcome was the change in clinical status based on a 7-category ordinal scale (1 = not hospitalised, resuming normal daily activities; 7 = deceased). The 35 patients enrolled from February 23 to March 20, 2020, included 18 in intensive care unit (ICU), and 17 in our infectious diseases ward (IDW). The 10-day course of remdesivir was completed by 22 patients (63 %) and discontinued by 13, of whom eight (22.8 %) discontinued because of adverse events. The median follow-up was 39 days (IQR 25–44). At day 28, 14 (82.3 %) patients from IDW were discharged, two were still hospitalized and one died (5.9 %), whereas in ICU 6 (33.3 %) were discharged, 8 (44.4 %) patients died, three (16.7 %) were still mechanically ventilated and one (5.6 %) was improved but still hospitalized. Hypertransaminasemia and acute kidney injury were the most frequent severe adverse events observed (42.8 % and 22.8 % of the cases, respectively). Our data suggest that remdesivir can benefit patients with SARS-CoV-2 pneumonia hospitalised outside ICU where clinical outcome was better and adverse events are less frequently observed. Ongoing randomised controlled trials will clarify its real efficacy and safety, who to treat, and when." @default.
• W3026005704 created "2020-05-21" @default.
• W3026005704 creator A5008126184 @default.
• W3026005704 creator A5010351936 @default.
• W3026005704 creator A5011663589 @default.
• W3026005704 creator A5014801178 @default.
• W3026005704 creator A5016846891 @default.
• W3026005704 creator A5018107636 @default.
• W3026005704 creator A5030113310 @default.
• W3026005704 creator A5034696950 @default.
• W3026005704 creator A5039849770 @default.
• W3026005704 creator A5042978214 @default.
• W3026005704 creator A5043751045 @default.
• W3026005704 creator A5044343619 @default.
• W3026005704 creator A5046364988 @default.
• W3026005704 creator A5046770468 @default.
• W3026005704 creator A5048814934 @default.
• W3026005704 creator A5051247475 @default.
• W3026005704 creator A5054484375 @default.
• W3026005704 creator A5055709893 @default.
• W3026005704 creator A5056509018 @default.
• W3026005704 creator A5062584952 @default.
• W3026005704 creator A5068011395 @default.
• W3026005704 creator A5069158223 @default.
• W3026005704 creator A5070384191 @default.
• W3026005704 creator A5072374977 @default.
• W3026005704 creator A5078788058 @default.
• W3026005704 creator A5082623681 @default.
• W3026005704 creator A5082761274 @default.
• W3026005704 date "2020-08-01" @default.
• W3026005704 modified "2023-10-03" @default.
• W3026005704 title "Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status" @default.
• W3026005704 cites W2102263282 @default.
• W3026005704 cites W2725497285 @default.
• W3026005704 cites W2793022939 @default.
• W3026005704 cites W2996400124 @default.
• W3026005704 cites W3000413850 @default.
• W3026005704 cites W3001897055 @default.
• W3026005704 cites W3003465021 @default.
• W3026005704 cites W3004280078 @default.
• W3026005704 cites W3004318991 @default.
• W3026005704 cites W3005212621 @default.
• W3026005704 cites W3007940623 @default.
• W3026005704 cites W3009199988 @default.
• W3026005704 cites W3009577418 @default.
• W3026005704 cites W3009885589 @default.
• W3026005704 cites W3010140478 @default.
• W3026005704 cites W3010233963 @default.
• W3026005704 cites W3010611713 @default.
• W3026005704 cites W3012379316 @default.
• W3026005704 cites W3018023298 @default.
• W3026005704 doi "https://doi.org/10.1016/j.phrs.2020.104899" @default.
• W3026005704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7212963" @default.
• W3026005704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32407959" @default.
• W3026005704 hasPublicationYear "2020" @default.
• W3026005704 type Work @default.
• W3026005704 sameAs 3026005704 @default.
• W3026005704 citedByCount "163" @default.
• W3026005704 countsByYear W30260057042020 @default.
• W3026005704 countsByYear W30260057042021 @default.
• W3026005704 countsByYear W30260057042022 @default.
• W3026005704 countsByYear W30260057042023 @default.
• W3026005704 crossrefType "journal-article" @default.
• W3026005704 hasAuthorship W3026005704A5008126184 @default.
• W3026005704 hasAuthorship W3026005704A5010351936 @default.
• W3026005704 hasAuthorship W3026005704A5011663589 @default.
• W3026005704 hasAuthorship W3026005704A5014801178 @default.
• W3026005704 hasAuthorship W3026005704A5016846891 @default.
• W3026005704 hasAuthorship W3026005704A5018107636 @default.
• W3026005704 hasAuthorship W3026005704A5030113310 @default.
• W3026005704 hasAuthorship W3026005704A5034696950 @default.
• W3026005704 hasAuthorship W3026005704A5039849770 @default.
• W3026005704 hasAuthorship W3026005704A5042978214 @default.
• W3026005704 hasAuthorship W3026005704A5043751045 @default.
• W3026005704 hasAuthorship W3026005704A5044343619 @default.
• W3026005704 hasAuthorship W3026005704A5046364988 @default.
• W3026005704 hasAuthorship W3026005704A5046770468 @default.
• W3026005704 hasAuthorship W3026005704A5048814934 @default.
• W3026005704 hasAuthorship W3026005704A5051247475 @default.
• W3026005704 hasAuthorship W3026005704A5054484375 @default.
• W3026005704 hasAuthorship W3026005704A5055709893 @default.
• W3026005704 hasAuthorship W3026005704A5056509018 @default.
• W3026005704 hasAuthorship W3026005704A5062584952 @default.
• W3026005704 hasAuthorship W3026005704A5068011395 @default.
• W3026005704 hasAuthorship W3026005704A5069158223 @default.
• W3026005704 hasAuthorship W3026005704A5070384191 @default.
• W3026005704 hasAuthorship W3026005704A5072374977 @default.
• W3026005704 hasAuthorship W3026005704A5078788058 @default.
• W3026005704 hasAuthorship W3026005704A5082623681 @default.
• W3026005704 hasAuthorship W3026005704A5082761274 @default.
• W3026005704 hasBestOaLocation W30260057041 @default.
• W3026005704 hasConcept C126322002 @default.
• W3026005704 hasConcept C177713679 @default.
• W3026005704 hasConcept C188816634 @default.
• W3026005704 hasConcept C194828623 @default.
• W3026005704 hasConcept C197934379 @default.
• W3026005704 hasConcept C2776376669 @default.
• W3026005704 hasConcept C2777080012 @default.

• next